Literature DB >> 10360640

Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture.

J D Bergström1, A Hermansson, T Diaz de Ståhl, N E Heldin.   

Abstract

Activation of Met by its ligand HGF has been shown to elicit both mitogenic and motogenic responses in thyrocytes in vitro. In the present study we have investigated the expression of Met in human anaplastic thyroid carcinoma cells in culture. There was a variation in expression level and size of Met in the different cell lines; high Met expression was found in four cell lines, compared to non-neoplastic human thyrocytes. Treatment with glucoproteinase F showed that the size differences observed were due to variances in the degree of glycosylation. Interestingly, in cell lines with high expression of Met, the receptor proteins were found to be constitutively tyrosine phosphorylated. None of these cell lines expressed HGF mRNA, and addition of suramin did not affect the level of tyrosine phosphorylation of Met in unstimulated cells, suggesting the absence of autocrine stimulatory pathways. Furthermore, we did not observe MET gene amplification, activating mutations or phosphatase defects. The tyrosine phosphorylated receptors appeared functionally active since the receptors associated with the adaptor molecule Shc. In summary, we have found ligand-independent constitutively activated Met in four out of six anaplastic thyroid carcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360640      PMCID: PMC2362268          DOI: 10.1038/sj.bjc.6690406

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  50 in total

1.  c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase.

Authors:  C Ponzetto; S Giordano; F Peverali; G Della Valle; M L Abate; G Vaula; P M Comoglio
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

2.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis.

Authors:  K M Weidner; S Di Cesare; M Sachs; V Brinkmann; J Behrens; W Birchmeier
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  A protein tyrosine phosphatase activity associated with the hepatocyte growth factor/scatter factor receptor.

Authors:  E Villa-Moruzzi; S Lapi; M Prat; G Gaudino; P M Comoglio
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

4.  Expression of the Met/HGF receptor in normal and neoplastic human tissues.

Authors:  M F Di Renzo; R P Narsimhan; M Olivero; S Bretti; S Giordano; E Medico; P Gaglia; P Zara; P M Comoglio
Journal:  Oncogene       Date:  1991-11       Impact factor: 9.867

5.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas.

Authors:  M F Di Renzo; M Olivero; S Ferro; M Prat; I Bongarzone; S Pilotti; A Belfiore; A Costantino; R Vigneri; M A Pierotti
Journal:  Oncogene       Date:  1992-12       Impact factor: 9.867

6.  Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells.

Authors:  N E Heldin; D Cvejić; S Smeds; B Westermark
Journal:  Endocrinology       Date:  1991-10       Impact factor: 4.736

7.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.

Authors:  S Rong; M Bodescot; D Blair; J Dunn; T Nakamura; K Mizuno; M Park; A Chan; S Aaronson; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

8.  Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains.

Authors:  A Bardelli; F Maina; I Gout; M J Fry; M D Waterfield; P M Comoglio; C Ponzetto
Journal:  Oncogene       Date:  1992-10       Impact factor: 9.867

9.  The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.

Authors:  M Prat; R P Narsimhan; T Crepaldi; M R Nicotra; P G Natali; P M Comoglio
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

10.  Evidence for the identity of human scatter factor and human hepatocyte growth factor.

Authors:  K M Weidner; N Arakaki; G Hartmann; J Vandekerckhove; S Weingart; H Rieder; C Fonatsch; H Tsubouchi; T Hishida; Y Daikuhara
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more
  8 in total

1.  Off-target effects of c-MET inhibitors on thyroid cancer cells.

Authors:  Yan Zhou; Conghui Zhao; Sigal Gery; Glenn D Braunstein; Ryoko Okamoto; Rocio Alvarez; Steven A Miles; Ngan B Doan; Jonathan W Said; Jiang Gu; H Phillip Koeffler
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

Review 2.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

3.  Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.

Authors:  Ian J Davis; Andrew W McFadden; Yixiang Zhang; Angela Coxon; Teresa L Burgess; Andrew J Wagner; David E Fisher
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

4.  Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.

Authors:  Mauro Papotti; Martina Olivero; Marco Volante; Francesco Negro; Maria Prat; Paolo M. Comoglio; Maria Flavia DiRenzo
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

5.  Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Authors:  Rebecca E Schweppe; Anna A Kerege; Vibha Sharma; Joanna M Poczobutt; Arthur Gutierrez-Hartmann; Rachel L Grzywa; Bryan R Haugen
Journal:  Thyroid       Date:  2009-08       Impact factor: 6.568

6.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Authors:  Gromoslaw A Smolen; Raffaella Sordella; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Heidi Archibald; Woo J Kim; Ross A Okimoto; Daphne W Bell; Dennis C Sgroi; James G Christensen; Jeffrey Settleman; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

7.  Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway.

Authors:  Yan-Tao Fu; Hai-Bo Zheng; Le Zhou; Da-Qi Zhang; Xiao-Li Liu; Hui Sun
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

8.  The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.

Authors:  Frédéric Relaix; Mariarosa Polimeni; Didier Rocancourt; Carola Ponzetto; Beat W Schäfer; Margaret Buckingham
Journal:  Genes Dev       Date:  2003-12-01       Impact factor: 11.361

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.